A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imbria Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines

• Ability to perform an upright treadmill cardiopulmonary exercise test

• Agreement to abide by contraceptive requirements

Exclusion Criteria:

• Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability

• Women who are pregnant, planning to become pregnant or lactating

• Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing